STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Co. - BMY STOCK NEWS

Welcome to our dedicated news page for Bristol-Myers Squibb Co. (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bristol-Myers Squibb Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bristol-Myers Squibb Co.'s position in the market.

News
Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
Rhea-AI Summary
Bristol Myers Squibb (BMY) completes the acquisition of RayzeBio, Inc. (RYZB) to strengthen its oncology pipeline with radiopharmaceutical therapeutics. The acquisition includes RYZ101, a promising RPT targeting somatostatin receptor 2 in GEP-NETs and ES-SCLC. Bristol Myers Squibb plans to leverage RayzeBio's IND engine and manufacturing facility to accelerate preclinical and clinical programs, offering growth opportunities in the coming years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
acquisition
-
News
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)
Rhea-AI Summary
Bristol Myers Squibb's Reblozyl receives positive CHMP recommendation for treating transfusion-dependent anemia in MDS patients in Europe, potentially expanding its indication. Results from the Phase 3 COMMANDS trial show significant improvement in transfusion independence and hemoglobin increase compared to epoetin alfa.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
-
News
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
Rhea-AI Summary
Bristol Myers Squibb (BMY) has completed the acquisition of RayzeBio, Inc. for approximately $4.1 billion, with 86% of RayzeBio's shares tendered. The transaction is expected to close on February 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
News
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI® (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or...
Rhea-AI Summary
Bristol Myers Squibb's KRAZATI (adagrasib) in combination with cetuximab receives priority review by the FDA for treating KRAS G12C-mutated colorectal cancer, with a target action date of June 21, 2024, based on positive results from the Phase 1/2 KRYSTAL-1 study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
Rhea-AI Summary
Bristol Myers Squibb (BMY) announces a public offering of senior unsecured notes totaling $13 billion to fund acquisitions and general corporate purposes. The offering includes nine tranches of notes with varying interest rates and maturity dates. The company plans to use the proceeds for proposed acquisitions of Karuna Therapeutics, Inc. and RayzeBio, Inc., as well as for general corporate needs. The offering is not contingent on the completion of the acquisitions, but failure to acquire Karuna by a specified date will trigger mandatory redemption of certain notes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
none
-
News
Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC
Rhea-AI Summary
Bristol Myers Squibb (BMY) received an unsolicited 'mini-tender' offer from Tutanota LLC to purchase up to 500,000 shares at $55 per share, significantly below market price. The offer is subject to conditions and may extend for 45-180 days. Shareholders are advised not to tender shares due to risks and potential delays.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
none
News
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
Rhea-AI Summary
Bristol Myers Squibb's Augtyro sNDA for NTRK-positive solid tumors accepted by the FDA with a target action date of June 15, 2024, based on positive results from TRIDENT-1 and CARE trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
none
-
News
VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence
Rhea-AI Summary
VantAI and Bristol Myers Squibb collaborate to discover molecular glues for therapeutic targets, with VantAI eligible to receive up to $674 million in milestone payments and royalties. The partnership combines VantAI's generative AI platform with Bristol Myers Squibb's expertise in targeted protein degradation to develop new small molecule therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
none
-
News
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
Rhea-AI Summary
Bristol Myers Squibb (BMY) and RayzeBio, Inc. (RYZB) announce the expiration of the waiting period under the HSR Act for BMY's tender offer to acquire RYZB for $62.50 per share in cash, totaling $4.1 billion. The transaction remains subject to the tender of a majority of RYZB's outstanding shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
News
Healthpeak Properties Reports Fourth Quarter and Year Ended 2023 Results
Rhea-AI Summary
Healthpeak Properties, Inc. (NYSE: PEAK) announced fourth-quarter and full-year 2023 financial results, including net income, Nareit FFO, FFO as Adjusted, AFFO, and Total Same-Store Portfolio Cash NOI growth. The company also highlighted lease executions, lab developments, joint ventures, net debt, and 2023 sustainability recognitions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
none
Stock BMY logo
Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

#129 Ranked by Market Cap
#4058 Ranked by Stock Gains
#576 Ranked by Dividends

BMY Stock Data

97.81B
2.02B
0.1%
78.93%
1.73%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About BMY

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.